Literature DB >> 29475065

Antiviral therapy improves survival in patients with HBV infection and intrahepatic cholangiocarcinoma undergoing liver resection: Novel concerns.

Meng Sha1, Seogsong Jeong1, Qiang Xia2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29475065     DOI： 10.1016/j.jhep.2018.01.039

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  7 in total

1.  Analysis of viral integration reveals new insights of oncogenic mechanism in HBV-infected intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma.

Authors:  Linghao Zhao; Yuyouye Wang; Tao Tian; Xinjie Rao; Wei Dong; Jinmin Zhang; Yuan Yang; Qifei Tao; Fang Peng; Chenhang Shen; Songbo Wang; Hui Liu; Xi Zeng; Weiping Zhou
Journal:  Hepatol Int       Date:  2022-09-20       Impact factor: 9.029

2.  lncRNA FLVCR1-AS1 regulates cell proliferation, migration and invasion by sponging miR-485-5p in human cholangiocarcinoma.

Authors:  Wenqing Bao; Feng Cao; Shubin Ni; Jing Yang; Haidong Li; Zhenxi Su; Bin Zhao
Journal:  Oncol Lett       Date:  2019-07-05       Impact factor: 2.967

3.  Long Non-Coding RNA PCAT6 Induces M2 Polarization of Macrophages in Cholangiocarcinoma via Modulating miR-326 and RhoA-ROCK Signaling Pathway.

Authors:  Jianfei Tu; Fazong Wu; Li Chen; Liyun Zheng; Yang Yang; Xihui Ying; Jingjing Song; Chunmiao Chen; Xianghua Hu; Zhongwei Zhao; Jiansong Ji
Journal:  Front Oncol       Date:  2021-01-21       Impact factor: 6.244

4.  Study on the Application of Doxorubicin-Loaded Magnetic Nanodrugs in Targeted Therapy of Liver Cancer.

Authors:  Lei Wang; Liping Liang; Shuzhen Shi; Chao Wang
Journal:  Appl Bionics Biomech       Date:  2022-02-22       Impact factor: 1.781

5.  Preoperative serum hepatitis B virus DNA was a risk factor for hepatocellular carcinoma recurrence after liver transplantation.

Authors:  Dali Zhang; Danni Feng; Minjuan Ren; Ying Bai; Zhenwen Liu; Hongbo Wang
Journal:  Ann Med       Date:  2022-12       Impact factor: 5.348

6.  Negative impact of hepatitis B surface seroclearance on prognosis of hepatitis B-related primary liver cancer.

Authors:  Cheng Lou; Tong Bai; Le-Wei Bi; Ying-Tang Gao; Zhi Du
Journal:  World J Clin Cases       Date:  2018-08-16       Impact factor: 1.337

7.  Real-world outcomes of patients with advanced intrahepatic cholangiocarcinoma treated with programmed cell death protein-1-targeted immunotherapy.

Authors:  Min Deng; Shaohua Li; Qiaoxuan Wang; Rongce Zhao; Jingwen Zou; Wenping Lin; Jie Mei; Wei Wei; Rongping Guo
Journal:  Ann Med       Date:  2022-12       Impact factor: 4.709
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.